Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Equity Average (2017 - 2025)

Historic Equity Average for Anaptysbio (ANAB) over the last 9 years, with Q3 2025 value amounting to -$37.1 million.

  • Anaptysbio's Equity Average fell 17867.6% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.1 million, marking a year-over-year decrease of 17867.6%. This contributed to the annual value of $79.5 million for FY2024, which is 5460.64% down from last year.
  • Per Anaptysbio's latest filing, its Equity Average stood at -$37.1 million for Q3 2025, which was down 17867.6% from -$5.4 million recorded in Q2 2025.
  • Over the past 5 years, Anaptysbio's Equity Average peaked at $389.3 million during Q1 2021, and registered a low of -$37.1 million during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $169.8 million (2023), whereas its average is $190.3 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 372.94% in 2021, then crashed by 17867.6% in 2025.
  • Quarter analysis of 5 years shows Anaptysbio's Equity Average stood at $370.0 million in 2021, then decreased by 27.07% to $269.9 million in 2022, then crashed by 61.37% to $104.2 million in 2023, then decreased by 25.54% to $77.6 million in 2024, then tumbled by 147.77% to -$37.1 million in 2025.
  • Its Equity Average was -$37.1 million in Q3 2025, compared to -$5.4 million in Q2 2025 and $52.4 million in Q1 2025.